Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC | OncLive

Dr. Luke Nordquist on the Impact of Additional Doses of Radium-223 in mCRPC

September 17, 2016

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

Luke Nordquist, MD, a urologic medical oncologist and CEO of the Urology Cancer Center and GU Research Network, discusses a prospective study looking at the impact of an additional 6 doses of radium-223 dichloride in patients with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases.

Radium-223 is currently approved at 50 kBq/kg monthly for 6 months in mCRPC. The study examined 44 patients who received an additional 6 doses of radium-223, and found that only 1 patient had confirmed radiographic progression.

Whether or not there is a therapeutic benefit is yet to be determined, says Nordquist.

Bayer is sponsoring a 3-arm study in which patients are assigned to the standard 50-kBq/kg dose for 6 doses, a higher dose of 80 kBq/kg for 6 doses, or the 50 kBq/kg dose for 12 doses. This will help provide us additional information of that topic.


x